News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Neuren Pharmaceuticals Limited to Move to Phase 2 Trial of NNZ-2566 on TBI
September 20, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Sydney, Sep 20, 2007 -- Neuren Pharmaceuticals has completed cohorts 1 and 2 of its Phase 1b trial to test the safety, tolerability and pharmacokinetic action of NNZ-2566 as a compound to treat traumatic brain injury (TBI).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Australia
MORE ON THIS TOPIC
IgA nephropathy
Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA
March 10, 2026
·
2 min read
·
Tristan Manalac
Insights
Single Pivotal Trials Demand Stronger Data and Risk Strategies
March 10, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Obesity
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
March 9, 2026
·
2 min read
·
Heather McKenzie
Weight loss
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China
March 9, 2026
·
2 min read
·
Annalee Armstrong
